Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Thrombosis and Haemostasis

• Publication date

  2013-06-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH12-11-0803PMID 23739841
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Warfarin in Patients with Atrial Fibrillation and Chronic Kidney Disease

  2014cited by this paper
• [New anticoagulants].

  2013cited by this paper
• [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism].

  2013cited by this paper
• Coronary artery calcification score and carotid intima–media thickness in patients with hemophilia

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Current understanding of thrombosis and hemostasis — from bench to bedside Polyphosphate : a link between platelets , coagulation and inflammation

  2012cited by this paper
• Dabigatran Etexilate

  2012cited by this paper
• Apixaban versus Warfarin in Patients with Atrial Fibrillation

  2012cited by this paper
• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Rare bleeding disorders

  2012cited by this paper
• Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation.

  2012cited by this paper
• Executive Summary Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

  2012cited by this paper
• Elevated factor VIII levels and risk of venous thrombosis

  2012cited by this paper
• Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.

  2012cited by this paper
• Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo

  2012cited by this paper
• Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

  2012cited by this paper
• Neutrophil extracellular trap (NET) impact on deep vein thrombosis.

  2012cited by this paper
• Antidote strategies to reverse anticoagulation with TB‐402, a long‐acting partial inhibitor of factor VIII

  2012cited by this paper
• Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait

  2012cited by this paper
• Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation.

  2012cited by this paper
• Single intravenous administration of TB‐402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose‐escalating, randomized, controlled trial

  2011cited by this paper
• Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

  2011cited by this paper
• A new exogen anticoagulant with high selectivity to intrinsic pathway of coagulation.

  2011cited by this paper
• Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.

  2011cited by this paper
• Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.

  2011influential reference
• Factor XI and XII as antithrombotic targets

  2011cited by this paper
• The factor XII -4C>T variant and risk of common thrombotic disorders: A HuGE review and meta-analysis of evidence from observational studies.

  2011cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2011cited by this paper
• The procoagulant and proinflammatory plasma contact system

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis.

  2011cited by this paper
• Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy.

  2011cited by this paper
• Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• How to prevent, treat, and overcome current clinical challenges of VTE

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis

  2010cited by this paper
• Comparative incidence of thrombosis in reported cases of deficiencies of factors of the contact phase of blood coagulation

  2010influential reference
• Coronary atherosclerosis and cardiovascular mortality in hemophilia

  2010cited by this paper
• Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis

  2010cited by this paper
• In vivo roles of factor XII.

  2010cited by this paper
• Subclinical deep venous thrombosis observed in 10% of hemophilic patients undergoing major orthopedic surgery

  2010cited by this paper
• Inhibition of Factor XIa as a New Approach to Anticoagulation

  2010cited by this paper
• A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo.

  2010cited by this paper
• Coagulation factor XI as a novel target for antithrombotic treatment

  2010cited by this paper
• Coagulation Factor IXa as a Target for Treatment and Prophylaxis of Venous Thromboembolism

  2010cited by this paper
• Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk.

  2010cited by this paper
• Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.

  2010cited by this paper
• Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

  2010cited by this paper
• Intrinsic Coagulation Activation and the Risk of Arterial Thrombosis in Young Women: Results From the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) Case-Control Study

  2010cited by this paper
• Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI.

  2009cited by this paper
• Relationship between Factor XII deficiency and thrombosis: the debate is still open?

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis

  2009cited by this paper
• Cardiovascular disease in patients with hemophilia

  2009cited by this paper
• The association of a mild FXII deficiency with myocardial infarction and venous thrombosis is completely unjustified

  2009cited by this paper
• Factor XI deficiency in humans

  2009cited by this paper
• A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons

  2009cited by this paper
• Factor XI deficiency--resolving the enigma?

  2009cited by this paper
• Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.

  2009cited by this paper
• Reduced incidence of ischemic stroke in patients with severe factor XI deficiency.

  2008cited by this paper
• Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Novel roles for factor XII-driven plasma contact activation system

  2008cited by this paper
• Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study

  2008cited by this paper
• Factor XI deficiency

  2008cited by this paper
• Drug therapy: Prevention and treatment of major blood loss

  2007cited by this paper
• Prevention and treatment of major blood loss.

  2007cited by this paper
• The intrinsic pathway of coagulation: a target for treating thromboembolic disease?

  2007cited by this paper
• Prevention and treatment of major blood loss.

  2007cited by this paper
• The plasma kallikrein–kinin system and risk of cardiovascular disease in men

  2007cited by this paper
• Evidence of a U‐shaped association between factor XII activity and overall survival

  2007cited by this paper
• nonvalvular atrial fibrillation

  2007cited by this paper
• Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis.

  2007cited by this paper
• Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII.

  2006influential reference
• Myocardial Infarction and Other Arterial Occlusions in Hemophilia A Patients

  2006cited by this paper
• Rare bleeding disorders

  2006cited by this paper
• Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis

  2006cited by this paper
• Non-catheter associated venous thrombosis in hemophilia A and B. A critical review of all reported cases

  2006cited by this paper
• Bleeding in carriers of hemophilia.

  2006cited by this paper
• Molecular diversity and accelerated evolution of C-type lectin-like proteins from snake venom.

  2005cited by this paper
• New anticoagulants.

  2005cited by this paper
• Defective thrombus formation in mice lacking coagulation factor XII

  2005cited by this paper
• Myocardial Infarction, Other Arterial Thrombosis and Invasive Coronary Procedures, in Hemaophilia B: A Critical Evaluation of Reported Cases

  2005cited by this paper
• Disruption of protein-membrane binding and identification of small-molecule inhibitors of coagulation factor VIII.

  2004cited by this paper
• Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo

  2004cited by this paper
• Neutrophil Extracellular Traps Kill Bacteria

  2004cited by this paper
• Decreased mortality of ischaemic heart disease among carriers of haemophilia.

  2003cited by this paper
• Complications of central venous access devices in paediatric haemophilia patients

  2003cited by this paper
• Inherited factor XI deficiency confers no protection against acute myocardial infarction

  2003cited by this paper
• Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model.

  2002cited by this paper
• FXI Is Essential for Thrombus Formation Following FeCl3-Induced Injury of the Carotid Artery in the Mouse

  2002cited by this paper
• Central venous catheter‐associated thrombosis in severe haemophilia

  1999cited by this paper
• Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation.

  1998cited by this paper
• A factor IX-deficient mouse model for hemophilia B gene therapy.

  1997cited by this paper
• A murine model of factor XI deficiency.

  1997cited by this paper
• Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules.

  1995cited by this paper
• Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A

  1995cited by this paper
• Definition of the Bleeding Tendency in Factor XI-Deficient Kindreds–A Clinical and Laboratory Study

  1995cited by this paper
• Assembly of contact-phase factors on the surface of the human neutrophil membrane.

  1994cited by this paper

• Circulating prekallikrein levels are correlated with lipid levels in the chinese population: a cross-sectional study

  2023cites this paper
• Pathophysiological Changes in the Hemostatic System and Antithrombotic Management in Kidney Transplant Recipients

  2022cites this paper
• Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence

  2022cites this paper
• Unveiling the Disaccharide-Branched Glycosaminoglycan and Anticoagulant Potential of Its Derivatives.

  2021cites this paper
• A novel rationale for targeting FXI: Insights from the hemostatic miRNA targetome for emerging anticoagulant strategies.

  2020cites this paper
• Blood Coagulation and Blood–Material Interactions

  2020cites this paper
• Thrombus

  2020cites this paper
• Novel Antithrombotic Strategies for Treatment of Venous Thromboembolism.

  2020cites this paper
• INFLUENCE OF HEPARINOID FROM PAEONIA LACTIFLORA ON HEMOSTATIC SYSTEM WITHIN CONDITIONS OF PRETHROMBOSIS

  2019cites this paper
• From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors.

  2019cites this paper
• ВЛИЯНИЕ ГЕПАРИНОИДА ИЗ ПИОНА (PAEONIA LACTIFLORA) НА СИСТЕМУ ГЕМОСТАЗА В УСЛОВИЯХ ПРЕДТРОМБОЗА

  2019cites this paper
• Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke

  2019cites this paper
• Title: Coagulation factor XII, XI, and VIII activity levels and secondary events after first ischemic stroke Authors:

  2019cites this paper
• Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present)

  2019cites this paper
• Advances in Antithrombotic Therapy

  2019cites this paper
• University of Birmingham Atherothrombosis and Thromboembolism :

  2018cites this paper
• The coagulation system in atherothrombosis: Implications for new therapeutic strategies

  2018cites this paper
• Microfluidics in coagulation monitoring devices: a mini review

  2018cites this paper
• A novel rationale for targeting FXI: Insights from the hemostastic miRNA targetome for emerging anticoagulant strategies

  2018cites this paper
• Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

  2018cites this paper
• Biophysical mechanisms of contact activation of blood-plasma clotting

  2017cites this paper
• AutoGPA-Based 3D-QSAR Modeling and Molecular Docking Study on Factor Xa Inhibitors as Anticoagulant Agents

  2016cites this paper
• Coagulation Factor XII –A Key Pro-Inflammatory and Pro-Coagulant Protein

  2016cites this paper
• Fasxiator, a novel factor XIa inhibitor from snake venom, and its site‐specific mutagenesis to improve potency and selectivity

  2015cites this paper
• Nowe perspektywy leczenia przeciwzakrzepowego — środki hamujące czynnik krzepnięcia XI

  2015cites this paper
• Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.

  2015cites this paper
• Ecotin: Exploring a feasible antithrombotic profile.

  2015cites this paper
• Is there a need for an alternative in the era of novel anticoagulants?

  2015cites this paper
• Coagulation factor XII protease domain crystal structure

  2015cites this paper
• Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit

  2015cites this paper
• Factor XI as target for antithrombotic therapy

  2014cites this paper
• Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides

  2014cites this paper
• Contact activation of blood coagulation on a defined kaolin/collagen surface in a microfluidic assay.

  2014cites this paper
• Characterization of the Functional Roles of Histidine-Rich Glycoprotein in Coagulation

  2014cites this paper
• UvA-DARE ( Digital Academic Repository ) Factor XI as target for antithrombotic therapy

  2014cites this paper
• Thrombin Generation by Gentamicin

  2014cites this paper
• Monitoring thrombin generation and screening anticoagulants through pulse laser-induced fragmentation of biofunctional nanogold on cellulose membranes.

  2014cites this paper
• No contact, no thrombosis?

  2014cites this paper
• Factor XI Regulates Pathological Thrombus Formation on Acutely Ruptured Atherosclerotic Plaques

  2014cites this paper